GeneDx Holdings Corp. - Class A Common Stock (WGS)
100.00
-2.22 (-2.17%)
NASDAQ · Last Trade: Apr 16th, 1:54 PM EDT
Detailed Quote
Previous Close
102.22
Open
98.48
Bid
99.64
Ask
100.35
Day's Range
97.06 - 101.37
52 Week Range
8.633 - 115.60
Volume
325,381
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
750,954
Chart
About GeneDx Holdings Corp. - Class A Common Stock (WGS)
GeneDx Holdings Corp. is a genomics company that specializes in providing genetic testing services to aid in the diagnosis and treatment of various genetic disorders. By leveraging advanced genomic technologies and bioinformatics, the company aims to deliver accurate and comprehensive genetic information that helps clinicians make informed decisions about patient care. GeneDx focuses on enhancing the understanding of rare and hereditary diseases, facilitating personalized medicine, and improving patient outcomes through insightful genomic data services. Read More
GeneDx (NASDAQ: WSG) to acquire Fabric Genomics, pioneer in AI-powered genomic interpretation, for up to $51 million. Expanding global reach and improving precision diagnostics.
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its plans to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation. The transaction enables GeneDx’s leadership in the next phase of genomic medicine: decentralized testing with centralized intelligence.
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2025 before the market opens on Wednesday, April 30, 2025. Management will host a conference call that day to discuss first quarter 2025 financial and operating results at 8:30 a.m. Eastern Time.
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the commercial expansion into Inborn Errors of Immunity (IEI), a group of nearly 500 genetic disorders that impair immune function2, increasing susceptibility to infections, autoimmunity, and inflammatory conditions. The strategic expansion reinforces GeneDx’s mission to improve patient outcomes by providing exome and genome testing solutions for an ever-growing number of patients, now including those with inherited immunological conditions.
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of March 15, 2025, the compensation committee of GeneDx’s board of directors granted 46,340 restricted stock units (“RSUs”) to ten newly-hired employees as inducements material to each employee entering into employment with GeneDx. The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today they have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025, and recognized as the No. 2 in the Biotech category. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the economy.
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its scientific contributions will be presented at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. GeneDx will showcase its leadership in genomic research and innovation, driving the industry forward with three platform presentations and two poster presentations.
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision support tool designed to revolutionize genetic analysis by improving diagnostic efficiency, streamlining workflows, and enhancing clinical insights. Multiscore is embedded into GeneDx’s interpretation platform as a decision support tool to help clinical geneticists focus on the most relevant genes during their clinical analysis. GeneDx will present the AI-powered decision support tool at ACMG, in a session: Multiscore, a Gene Ranker Powered by Artificial Intelligence and Real-World Clinical Data, Shows High Sensitivity in 10,000 Exomes and Genomes which received one of the limited spots in an industry-specific platform session.
In this video lesson I review the day-one of a new rally attempt in the overall market, discuss my new swing trade in a cyber-security leader, and review my tier-one long-term portfolio purchases in my favorite leading stocks before the closing bell.
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today an indication expansion for its industry leading genetic testing to now include cerebral palsy (CP). In conjunction with Cerebral Palsy Awareness Month, the company is expanding its strategy of focusing on pediatric rare disease patients to now include offering testing for pediatric patients with CP. This strategic indication expansion underscores the importance of improving access to exome and genome testing for patients with CP to shorten the diagnostic odyssey and accelerate the path to treatment.
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the American Journal of Human Genetics published peer-reviewed research from the Seqfirst-neo study conducted in partnership with Seattle Children’s and the University of Washington. Seqfirst-neo is a pioneering study focused on the application of rGS in NICU settings to improve access to a genetic diagnosis overall and specifically in underserved communities to reduce missed diagnoses and improve clinical outcomes for patients.
Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday.
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024.
